As the global demand for GLP-1 drugs continues to grow, LC-MS characterization will remain a key component of regulatory compliance, biosimilar comparison, and pharmaceutical quality assurance
It works through growth hormone pathways, not sex hormone production
In the STEP 1 trial, once weekly GLP-1 agonist at 2.4 mg with lifestyle intervention led to a mean body weight reduction of 14.9 percent at 68 weeks, compared with 2.4 percent with placebo 2
While evidence-based interventions are largely restricted to educational and behavioral programs, many individuals with ASD and their caregivers explore complementary approaches, including dietary interventions
By repressing cardiac peroxisome proliferator-activated receptor-, miR-199a facilitates a metabolic shift from a predominant reliance on fatty acid utilization toward an increased reliance on glucose metabolism, which leads to lethal heart failure (36)